Ticho Barry 4

4 · Stoke Therapeutics, Inc. · Filed Mar 19, 2026

AI-generated summary of this filing

Updated Mar 19, 2026

Stoke Therapeutics (STOK) CMO Ticho Barry Sells Shares, Exercises Options

What Happened

Ticho Barry, Chief Medical Officer of Stoke Therapeutics (STOK), reported multiple open‑market sales and an option/derivative exercise between March 17–19, 2026. He sold a total of 14,311 shares in several transactions (aggregate proceeds ≈ $456,835). On March 19 he also exercised/converted 1,365 derivative shares at $2.19 per share (total paid ≈ $2,989).
These were predominantly sales (routine/liquidity), with a small option exercise (acquisition). Some sales were related to tax withholding on vested awards and at least one transaction was executed under a Rule 10b5‑1 plan.

Key Details

Transaction dates and amounts:
- 2026-03-17: Sold 3,577 shares @ $32.74 = $117,109 (weighted avg pricing noted)
- 2026-03-17: Sold 2,587 shares @ $33.38 = $86,342 (weighted avg)
- 2026-03-18: Sold 6,100 shares @ $31.28 = $190,831 (weighted avg)
- 2026-03-18: Sold 483 shares @ $31.79 = $15,354
- 2026-03-18: Sold 103 shares @ $32.85 = $3,384
- 2026-03-19: Exercised/converted 1,365 shares @ $2.19 (Acquired) = $2,989
- 2026-03-19: Sold 1,461 shares @ $29.99 = $43,815
- 2026-03-19: A derivative disposition of 1,365 shares recorded at $0 (reported as a derivative transaction)
Aggregate: 14,311 shares sold for ≈ $456,835; 1,365 shares acquired via exercise for ≈ $2,989.
Shares owned after the transactions: not specified in the filing.
Notable footnotes from the filing:
- F1: Some sales were issuer‑mandated to satisfy tax withholding on vesting/settlement of restricted stock units.
- F2–F5: Reported prices are weighted averages; the filing gives specific price ranges for multiple trade blocks.
- F6: At least one sale was executed under a Rule 10b5‑1 trading plan adopted Nov 19, 2025.
- F7: The option exercised is fully vested and exercisable.
Filing timeliness: Form 4 was filed on March 19, 2026 for transactions dated Mar 17–19, 2026 — within the normal 2‑business‑day filing window (not flagged as late).

Context

Sales by executives are common for liquidity or tax purposes; here the filing explicitly notes issuer‑mandated sales to cover taxes and a 10b5‑1 plan for at least one transaction. Those circumstances typically indicate routine reasons rather than a direct statement about the executive’s view of the company.
For the derivative activity: the filing shows an exercise/conversion (1,365 shares acquired at $2.19) plus a related derivative disposition recorded at $0; footnotes indicate the option was fully vested. This pattern can reflect exercise/settlement mechanics (including any net or cashless settlement or conversion), but the filing provides the facts without stating a motive.

Form 4

Period: 2026-03-17

CHIEF MEDICAL OFFICER

Transactions

Sale
Common Stock
[F1][F2]
2026-03-17$32.74/sh−3,577$117,109→ 50,071 total
Sale
Common Stock
[F1][F3]
2026-03-17$33.38/sh−2,587$86,342→ 47,484 total
Sale
Common Stock
[F1][F4]
2026-03-18$31.28/sh−6,100$190,831→ 41,384 total
Sale
Common Stock
[F1][F5]
2026-03-18$31.79/sh−483$15,354→ 40,901 total
Sale
Common Stock
[F1]
2026-03-18$32.85/sh−103$3,384→ 40,798 total
Exercise/Conversion
Common Stock
[F6]
2026-03-19$2.19/sh+1,365$2,989→ 42,163 total
Sale
Common Stock
[F6]
2026-03-19$29.99/sh−1,461$43,815→ 40,702 total
Exercise/Conversion
Stock Option (Right to Buy)
[F6][F7]
2026-03-19−1,365→ 83,035 total
Exercise: $2.19Exp: 2028-12-11→ Common Stock (1,365 underlying)

Footnotes (7)

[F1]The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.
[F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.
[F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.
[F6]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
[F7]The option is fully vested and exercisable.

Signature

/s/ Jonathan Allan, Attorney-in-Fact|2026-03-19

1 file